Ascendis Pharma A/S (ASND) Stock Price & How to Invest

Ascendis Pharma A/S trades on Nasdaq under ASND as American Depositary Shares, each representing one ordinary share of a company headquartered in Hellerup, Denmark. The business is built on TransCon, a prodrug technology that attaches a known parent drug to a carrier through a linker that releases the active molecule slowly and predictably, which lets Ascendis convert daily injections into weekly or monthly dosing. Three products are approved and marketed: SKYTROFA (lonapegsomatropin) for pediatric growth hormone deficiency, YORVIPATH (palopegteriparatide) for adult hypoparathyroidism, and YUVIWEL (navepegritide, developed as TransCon CNP), which received accelerated FDA approval with orphan exclusivity in May 2026 for pediatric achondroplasia. Trailing twelve month revenue is roughly ~EUR 866 million (about ~$1.0 billion), up roughly ~135 percent year over year, with gross margin near ~89 percent.

The growth is concentrated in one product. In the first quarter of 2026 Ascendis reported total revenue of roughly ~EUR 247 million, of which YORVIPATH contributed roughly ~EUR 197 million and SKYTROFA roughly ~EUR 44 million. Reported net profit of roughly ~EUR 629 million that quarter was dominated by a one-time recognition of a roughly ~EUR 679 million deferred tax asset, and management pointed to non-IFRS net profit of roughly ~EUR 18 million as the closer read on underlying operations. That distinction matters when reading the headline trailing price to earnings ratio near ~28, because the earnings underneath it are largely an accounting event rather than cash. The company also agreed to sell a Rare Pediatric Disease Priority Review Voucher for roughly ~$187.5 million, a familiar rare-disease funding lever. Second quarter 2026 results were scheduled for August 13, 2026, so the most recent reported period as of this writing is the first quarter.

Revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model. AstraZeneca's eneboparatide and other parathyroid hormone programs target the same indication, while BioMarin's Voxzogo is entrenched in achondroplasia and a long-acting successor is in development, and oral FGFR3 approaches from companies including Tyra Biosciences could reframe the category entirely. YUVIWEL was cleared under accelerated approval, which carries confirmatory evidence obligations that can constrain or withdraw a label. Ascendis is a foreign private issuer that reports in euros and files Form 20-F, so currency translation and a lighter interim disclosure cadence than a domestic filer both apply. On the legal side, Ascendis is an appellant in patent litigation against BioMarin at the Federal Circuit (No. 26-1026), and plaintiffs' firms publicized securities class action investigation notices in 2023 following the FDA deficiency letter on TransCon PTH, though those solicitations are not the same as a filed complaint and no active securities-fraud class action was identified as of August 2026.

18 analysts publish price targets on ASND, averaging $309.06 against a $255.41 price as of August 2026, or +21.0%. The published targets run from $261.24 to $358.98, a moderate spread, and the ratings split 18 buy, 0 hold, 0 sell. Over the last six months there have been 6 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ASND forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Ascendis Pharma A/S. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. YORVIPATH is carrying the model. Hypoparathyroidism had no chronic hormone-replacement standard for years after Takeda withdrew Natpara, leaving a diagnosed population managed on calcium and active vitamin D. The most optimistic published target, $358.98, assumes this works close to its best case.

The case against. Revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model. The most pessimistic target, $261.24, is roughly what ASND is worth if this bites instead.

Read the full bull and bear case on ASND, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Ascendis Pharma A/S's investor relations page or your broker.

• Market cap: ~$16.8 billion
• Revenue (TTM): ~EUR 866 million (about ~$1.0 billion), up ~135% year over year
• Most recent reported quarter (Q1 2026): Revenue ~EUR 247 million; YORVIPATH ~EUR 197 million, SKYTROFA ~EUR 44 million
• Profitability: Gross margin ~89%, operating margin ~-1.7%; Q1 non-IFRS net profit ~EUR 18 million
• Valuation multiples: Price to sales ~16.9x, forward price to earnings ~38x, trailing price to earnings ~28x (distorted by a one-time tax item)
• Balance sheet: Cash ~$660 million against total debt ~$1.03 billion, net debt ~$373 million; ~65.9 million shares outstanding

The trailing earnings multiple is the number most likely to mislead here, because reported net income of roughly ~EUR 496 million on a trailing basis is driven largely by the roughly ~EUR 679 million deferred tax asset recognized in the first quarter of 2026, not by operations. Price to sales near ~17x and forward price to earnings near ~38x are the cleaner framing, and both price in continued rapid growth from a base that has already tripled. Second quarter 2026 results, scheduled for August 13, 2026, are the next data point on whether the YORVIPATH ramp is holding and how YUVIWEL is converting enrollments into revenue.

Other names that sit close to ASND: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ASND exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ASND sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ASND fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Ascendis has crossed from clinical promise to real product revenue, and the open question is whether launch economics can grow into a market capitalization of roughly ~$16.8 billion.

Whether ASND is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ASND a buy or a sell?, and where the stock could go from here in the ASND stock forecast.

For income investors, whether ASND pays a dividend and how the payout looks is covered in does ASND pay a dividend? And to weigh ASND against a peer, read the full side-by-side comparisons: ASND vs AZN and ASND vs NVO.